Chemistry:BMS-986278

From HandWiki
Short description: Chemical compound
BMS-986278
BMS-986278.svg
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H31N5O5
Molar mass445.520 g·mol−1
3D model (JSmol)

BMS-986278 is an experimental small-molecule drug and lysophosphatidic acid receptor 1 (LPA1) antagonist developed by Bristol Myers Squibb for idiopathic pulmonary fibrosis.[1][2][3]

References

  1. Murphy, Brian; Sum, Chi-Shing; Wang, Tao; Heiry, Rebekah; Kalinowski, Stephen; Hung, Chen-Pin; Chu, Ching-Hsuen; Azzara, Anthony et al. (28 September 2019). "LPA1 antagonist BMS-986278 for idiopathic pulmonary fibrosis: Preclinical pharmacological in vitro and in vivo evaluation". Idiopathic interstitial pneumonias. pp. PA5383. doi:10.1183/13993003.congress-2019.PA5383. 
  2. Cheng, Peter T. W.; Kaltenbach, Robert F.; Zhang, Hao; Shi, Jun; Tao, Shiwei; Li, Jun; Kennedy, Lawrence J.; Walker, Steven J. et al. (11 November 2021). "Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases". Journal of Medicinal Chemistry 64 (21): 15549–15581. doi:10.1021/acs.jmedchem.1c01256. PMID 34709814. 
  3. Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi et al. (December 2021). "Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)". BMJ Open Respiratory Research 8 (1): e001026. doi:10.1136/bmjresp-2021-001026. PMID 34969771.